Synonyms: BHBA-001 | BHBA001 | C-286 | C286 | compound 10 [PMID: 30792038] | KCL286
Compound class:
Synthetic organic
Comment: This compound is reported as an orally bioavailable retinoic acid receptor beta (RARβ) agonist, that activates the RARβ2 subtype [2] that is involved in neurite outgrowth/axonal regeneration [1,4]. It is predicted to stimulate nerve regrowth as a mechanism to treat spinal cord injuries.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
As KCL-286 the compound was progressed to clinical evaluation in study ISRCTN12424734 with study results published in August 2023 [3]. Tolerability, target engagement and receptor activation were confirmed in healthy study volunteers. |